Expression of semaphorin 3A and its receptors in the human intervertebral disc: potential role in regulating neural ingrowth in the degenerate intervertebral disc by Tolofari, Sotonye K et al.
Tolofari et al. Arthritis Research & Therapy 2010, 12:R1
http://arthritis-research.com/content/12/1/R1
Open Access RESEARCH ARTICLE
© 2010 Tolofari et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Research article Expression of semaphorin 3A and its receptors in 
the human intervertebral disc: potential role in 
regulating neural ingrowth in the degenerate 
intervertebral disc
Sotonye K Tolofari, Stephen M Richardson, Anthony J Freemont and Judith A Hoyland*
Abstract
Introduction: Intervertebral disc (IVD) degeneration is considered a major underlying factor in the pathogenesis of 
chronic low back pain. Although the healthy IVD is both avascular and aneural, during degeneration there is ingrowth 
of nociceptive nerve fibres and blood vessels into proximal regions of the IVD, which may contribute to the pain. The 
mechanisms underlying neural ingrowth are, however, not fully understood. Semaphorin 3A (sema3A) is an axonal 
guidance molecule with the ability to repel nerves seeking their synaptic target. This study aimed to identify whether 
members of the Class 3 semaphorins were expressed by chondrocyte-like cells of the IVD addressing the hypothesis 
that they may play a role in repelling axons surrounding the healthy disc, thus maintaining its aneural condition.
Methods: Human IVD samples were investigated using reverse transcription polymerase chain reaction (RT-PCR) to 
identify gene expression of sema3A, 3F and their receptors: neuropilins (1 and 2) and plexins (A1-4). Sema3A protein 
was also localised within sections of normal and degenerate human IVD and immunopositivity quantified. Serial 
sections were stained using PGP9.5 and CD31 to correlate semaphorin 3A expression with nerve and blood vessel 
ingrowth, respectively.
Results: Sema3A protein was expressed highly in the healthy disc, primarily localised to the outer annulus fibrosus. In 
degenerate samples, sema3A expression decreased significantly in this region, although cell clusters within the 
degenerate nucleus pulposus exhibited strong immunopositivity. mRNA for sema3A receptors was also identified in 
healthy and degenerate tissues. CD31 and PGP9.5 were expressed most highly in degenerate tissues correlating with 
low expression of sema3A.
Conclusions: This study is the first to establish the expression of semaphorins and their receptors in the human IVD 
with a decrease seen in the degenerate painful IVD. Sema3A may therefore, amongst other roles, act as a barrier to 
neuronal ingrowth within the healthy disc.
Introduction
Chronic low back pain (LBP) is a widespread problem
within the UK and epidemiological studies have shown
that it affects approximately 50 to 80% of adults during
their lifetime [1,2]. Low back pain may originate from
various sources and is considered to be multifactorial.
However, numerous studies using various imaging tech-
niques, primarily magnetic resonance imaging, have
shown that intervertebral disc (IVD) degeneration is one
of the major underlying factors in chronic non-specific
LBP, accounting for approximately 40% of all cases [3-6].
In the healthy adult, the IVD is largely avascular and
aneural with sparse innervation and vascularisation to
the outer lamellae of the annulus fibrosus (AF) [7]. Dur-
ing IVD degeneration a number of pathological processes
occur that impact on the extracellular matrix constitu-
ents, the macroscopic and histological appearance, and
ultimately the function of the IVD [8,9]. Evidence sug-
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gests that neoinnervation and neovascularisation may be
integral steps in the pathogenesis of painful IVD degener-
ation [10-13] with particular interest focussed on the
ingrowth of nociceptive nerve fibres and their association
with chronic low back pain [12,14,15]. Yet, despite these
studies the mechanism of neural and blood vessel
ingrowth still remains an enigma although it is assumed
that such ingrowth is stimulated or inhibited by a number
of physiological factors.
Numerous studies have investigated factors that may
stimulate neural ingrowth within the IVD. Immunohis-
tochemical and in situ hybridisation techniques have
demonstrated that endothelial cells accompanying nerves
growing proximally into the degenerate IVD express neu-
rotrophic factors such as nerve growth factor (NGF) [16].
Additional studies have also established the expression of
NGF in native nucleus pulposus (NP) and AF cells which
increases after stimulation with proinflammatory cytok-
ines which have been identified in IVD degeneration [17].
Other research has identified the upregulation of NGF
and brain-derived neurotrophic factor (BDNF) in degen-
erate discs when compared to a cohort of healthy samples
[18]. Noteworthy is the evidence which suggests that neu-
rotrophic factors may also induce nociception via upreg-
ulation of pain-related neuopepties such as substance P
and calcitonin gene related peptide (CGRP) [19]. Other
potentially stimulating factors for neural and vascular
ingrowth include the proinflammatory cytokines IL-1
and TNF-α [17,18,20]. Additionally, mast cells have also
been suggested as a stimuli for neural and vascular
ingrowth [21]. Plieotrophin and vascular endothelial
g r o w t h  f a c t o r  ( V E G F )  h a v e  a l s o  b e e n  s h o w n  t o  b e
expressed by disc cells which may contribute to neova-
sucularisation during disc degeneration [20,22,23].
In contrast to neural stimulation, an opposing mecha-
nism may be a lack of inhibitory factors influencing
encroaching nerves. There is a significant amount of evi-
dence illustrating that chondroitin sulphated proteogly-
cans such as aggrecan, which is found at high
concentrations within the NP, have the ability to inhibit
neural and vascular ingrowth [24-28]. In vitro studies
suggest that this inhibitory action is due to the direct
effect of the aggrecan molecule, as it prevents formation
and growth of axonal processes [28]. Aggrecan is known
to become depleted in the degenerate IVD, and hence as
aggrecan is lost, so are any inhibitory influences on
invading nerves and blood vessels. However, apart from
these studies into the inhibitory effects of aggrecan on
neuronal extension into the IVD, there is little additional
literature that investigates other potentially inhibitory
factors to nerves in the IVD.
Axons are capable of navigating through the developing
nervous system with extraordinary accuracy. This is par-
t i a l l y  d u e  t o  t h e  gu i d a n c e  o f  m o l ec u l e s  s u c h  a s  s e m a -
phorins. Semaphorins, formerly known as collapsins, are
a large family consisting of eight classes of secreted and
membrane bound polypeptides that have been identified
in both invertebrates and vertebrates. This family, Class 3
semaphorins (sema3), are a large subgroup of these poly-
peptides, containing members A-G, which are the only
secreted form of semaphorins found in vertebrates. These
semaphorins were originally characterised in the devel-
oping nervous system, dorsal root ganglion, peripheral
and sympathetic nervous systems as chemorepellent mol-
ecules that acted to initiate axonal collapse in areas that
they were found in high concentration, thus resulting in
axonal guidance [29-31]. This phenomenon has been out-
lined in studies that have demonstrated that sema3A null
mutant mice showed extensive defasiculation of periph-
eral nerves and branching of axons into territories nor-
mally avoided by healthy nerves [29], thus demonstrating
that sema3A is important in controlling nerve growth by
facilitated repulsion of the axonal growth cone. Although
originally reported as being responsible solely for axonal
guidance in the developing nervous system [30,31] recent
evidence suggests that they have a more pleiotrophic
nature, fulfilling many additional roles including regula-
tion of angiogenesis, organogenesis, tumurogenesis, cell
migration, cytokine release and immune modulation [32-
35]. However, despite the increasing evidence base
regarding the different functions of the semaphorins
within the human body, from a review of current litera-
ture it seems that the complete in vivo biological role of
these molecules still remains unclear.
There are two families of receptors to the Class 3 sema-
phorins that are usually found on developing axons, the
first of which being the neuropilins (NRP) and the second
being the plexins (PLX). The neuropilins consist of two
members; NRP1 which is thought to be the principal
receptor for sema3A and NRP2 which is thought to be
the principal receptor for sema3F [36-39]. The mamma-
lian plexins consist of nine members PLXA(1-4),
PLXB(1-3), PLXC1 and PLXD1 [36-43]. Evidence sug-
gests that the neuropilins lack a defined signalling ability
themselves and must bind with plexins in order to form a
multimeric  holoreceptor  signalling complex. This com-
plex facilitates a signalling cascade which is thought to
initiate rapid depolymerisation and endocytosis of F-
actin, thus inducing cytoskeletal collapse of the axon
[39,40,44]. Interestingly, as well as binding members of
the PLX family the NRPs bind VEGF receptors to
enhance VEGF165 activity suggesting they also play a role
in regulating angiogenesis through the competitive inhi-
bition of sema3A and VEGF against one another for over-
lapping binding sites on the NRP molecule [45,46].
Recent evidence has identified sema3A, 3F and a num-
ber of its receptors in multiple cell types during endo-
chondral ossification [47]. Importantly, prehypertrophicTolofari et al. Arthritis Research & Therapy 2010, 12:R1
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and hypertrophic chondrocytes demonstrated positivity
for the semaphorins which preceeded neurovascular
invasion. As IVD cells are phenotypically similar to chon-
drocytes [48] we hypothesised that cells of the healthy
IVD may express semaphorins as a means of repelling
neurovascular invasion, and in disc degeneration the
expression of semaphorins may be reduced causing a dis-
inhibition of neural and vascular ingrowth. As such the
aim of this study was to investigate the expression of
semaphorin 3A and 3F and their receptors in the human
IVD and to ascertain whether expression altered within
different IVD regions or with severity of degeneration.
IVD samples were also analysed by immunohistochemis-
try for PGP9.5 and CD31 to correlate semaphorin 3A
expression with nerve and blood vessel ingrowth respec-
tively.
Materials and methods
Human IVD tissue was obtained at either post mortem or
f o l l o w i n g  s u r g e r y ,  w i t h  i n f o r m e d  c o n s e n t  f r o m  t h e
patient or relatives. Local research ethics approval (North
West Research Ethics Committee) was obtained for this
work. Post-mortem samples of normal and degenerate
NP were obtained within 18 hours of donor death.
Asymptomatic normal and degenerate discs obtained
from donors at PM had no documented clinical history of
LBP . Samples of degenerate NP were also obtained from
patients, diagnosed by magnetic resonance imaging, who
underwent disc replacement surgery or spinal fusion to
relieve chronic low back pain. Patients suffering from
classical sciatica were excluded from the study. All sam-
ples were obtained and processed as previously described
in studies conducted by our group [49].
Histological grading of NP tissues
To establish histological grade of degeneration NP sam-
ples were fixed in 4% paraformaldehyde/PBS and pro-
cessed into paraffin wax. Five micron sections from the
tissue blocks were cut and stained with haematoxylin and
eosin and the degree of morphological degeneration
graded according to previously published criteria [48].
The grading system generates a score between 0 and 12: a
grade of 0 to 3 represents a histologically normal (non-
degenerate) disc grades of 4 to 6 indicate mild degenera-
tion, grades 7 to 9 moderate degeneration and grades 10
to 12 severe degeneration.
RT-PCR
A range of post-mortem and surgical samples were used,
in which there were 14 samples (7 AF and 7 NP) in each
cohort. The post mortem cohort ranged from aged 30 to
79 years (mean: 57 years) and the surgical cohort ages 29
to 56 years (mean: 39 years). Cells were isolated from
each sample as previously reported [49] and RNA
extracted using Trizol™ (Invitrogen, Paisley, UK) accord-
ing to the manufacturer's instructions. RNA was then
treated with 4U DNAse I (Invitrogen) to remove any
DNA contamination and reverse transcribed using an
Applied Biosystems (Warrington, UK) High Capacity
cDNA Reverse Transcription kit as per the manufac-
turer's instructions.
Aliqouts of cDNA were subjected to PCR using primers
specific for the house-keeping gene GAPDH, as well as
sema3A, sema3F, NRP-1, NRP-2, PLXA1, PLXA2,
PLXA3, PLXA4 and PGP9.5 (Table 1). Each 25 μl reaction
mixture consisted of: 19.125 μl molecular biology grade
water, 2.5 μl 10 × PCR buffer w/o MgCl2, 0.75 μl 50 mM
Table 1: Human oligonucleotide primer sequences used for RT-PCR
Primer Name Forward Primer Reverse Primer Amplicon 
Size (bp)
Genbank Accession Number
GAPDH GCCTCCTGCACCACCAAC GAGCTTGACAAAGTGGTCG 482 [Genbank: NM_002046]
SemaA GAGACTTGGTATGATTTAGAAG GCTCTGTGTCAATGACTTCC 618 [Genbank: NM_006080]
SemaF AGTGTCCGTACGATCCCAAG CAACAGTGACCACCGTCATC 328 [Genbank: NM_004186]
NRP-1 CTCCTGTTGTGTCTTCAGG CCCGATGAGGATCGGATTC 396 [Genbank: NM_003873]
NRP-2 CATGCACTATGACACCCCTG ATGGGTTCCATGCAGTTCTC 756 [Genbank: NM_201266]
PLXA1 GACTTCCTGCTGACCCTGAG GACTTCAACCTGAAGCCAGC 689 [Genbank: NM_032242]
PLXA2 GCTACAAGAGCTGGGTGGAG CTCTCGGCTTGAAGAACCAC 538 [Genbank: NM_025179]
PLXA3 CAGCAGATCGACTACAAGAC GCCGTGTCAGGTAGATCTC 564 [Genbank: NM_017514]
PLXA4 TGTCAGGTGTCAACGAGAGC ATACACCTGCTCCTTGGTGG 350 [Genbank: NM_020911]
PGP9.5 TGCTGAACAAAGTGCTGTCC AAAGGCATTCGTCCATCAAG 508 [Genbank: NM_004181]Tolofari et al. Arthritis Research & Therapy 2010, 12:R1
http://arthritis-research.com/content/12/1/R1
Page 4 of 11
MgCl2, 1 μl 5 mM dNTP mix, 0.25 μl of 100 μM respec-
tive forward and reverse primers, 0.125 μl Platinum Taq
polymerase (Invitrogen) and 1 μl of respective cDNA (5
ng/μl). Articular cartilage cDNA and molecular grade
water were used as positive and negative controls respec-
tively. Amplification was performed in a thermal cycler
(Veriti, Applied Biosystems, UK) under the following
conditions: enzyme activation at 95°C for 90 seconds fol-
lowed by 38 cycles of 95°C for 20 seconds, 60°C for 20
seconds and 72°C for 60 seconds; and a final extension
step of 72°C for 10 minutes. PCR products were then run
on a 2% agarose gel containing GelRed (Biotium, Hay-
ward, CA, USA) alongside a 100 bp DNA ladder (Bioline
Hyperladder IV, London, UK). Bands were visualised by
UV transillumination and images acquired using
Genesnap software (Syngene, Cambridge, UK).
Immunohistochemistry
Immunohistochemistry for sema3A, PGP 9.5 and CD31
was conducted on cohorts of healthy and degenerate disc
tissue. The healthy disc cohort consisted of 10 healthy
samples which were histologically graded between 0 and
3 according to previously published criteria [48] and had
an age range of 30 to 61 years (mean: 51 years). There
were a further 10 samples considered to be mildly degen-
erate (grades 4 to 6) ranging from ages 30 to 74 years
(mean: 53 years), a moderately degenerate cohort of 10
samples (grades 7 to 9) ranging from ages 28 to 79 years
(mean: 61 years) and a severely degenerate cohort (grades
10 to 12) of 10 samples ranging from ages 22 to 78 years
(mean: 41 years). The latter two cohorts primarily con-
sisted of samples obtained during surgery. The immuno-
histochemistry protocol followed was as previously
published [49,50]. Antigen retrieval was performed using:
type II trypsin for sema3A (1 mg/ml for 20 minutes at
37°C), heated citrate buffer for PGP9.5 (10% v/v citrate
buffer pH6.0 for 15 minutes at 95°C) and pepsin for CD31
(1 mg/ml in 0.2 M HCL for an hour at 37°C). Subse-
quently, the slides were washed with tris-buffered saline
(TBS) and non-specific secondary antibody binding was
blocked with 25% normal goat serum diluted in 1%
bovine serum albumin (BSA)/TBS for sema3A & PGP9.5
and 10% normal goat serum diluted in 1% BSA/TBS for
CD31. Each primary antibody was diluted in 1% BSA/
TBS. Sema3A was applied at a 1:250 dilution, PGP9.5 at
1:20 and CD31 at 1:10 and incubated at 4°C overnight.
Slides were then washed with TBS and the biotinylated
secondary antibody was applied: goat anti-rabbit
(sema3A) and goat anti-mouse (CD31/PGP9.5). Both
antibodies were applied at a 1:300 dilution in TBS. Posi-
tive controls included rat brain for sem3A, human tonsil
for CD31 and human brain for PGP9.5. Binding of the
secondary antibody was disclosed with the streptavidin-
biotin complex (Vector Laboratories, Peterborough, UK)
technique with 3,3'-diaminobenzidine tetrahydrochloride
solution (Sigma, Poole, Dorset, UK). Sections were coun-
terstained with Mayer's haematoxylin (Raymond A.
Lamb, East Sussex, UK), dehydrated, and mounted with
Pertex (CellPath Plc, Powys, UK).
Quantitative analysis of staining was performed and for
each section five random fields of view were observed in
each morphologically distinct region of the disc (nucleus
pulposus (NP), inner annulus fibrosus (IAF), outer annu-
lus fibrosus (OAF)). Two hundred cells were counted per
region and the percentage of positive cells was then cal-
culated for each region of the IVD. Statistically, the data
were non-parametric and analysed using the Wilcoxon
matched pairs test when comparing data within regions
of the disc. Additionally, the Mann-Whitney U test was
used to compare data across varying grades of degenera-
tion. Data were then plotted as mean ± standard errors to
represent the 95% confidence intervals.
Results
Gene Expression of sema3A and 3F in IVD samples
Sema3A was expressed in 86% (6/7) of the healthy AF
samples and 57% (4/7) of the healthy NP samples (Figure
1). Sema3F expression was observed in three (43%) of
healthy AF samples and no expression was detected in
the healthy NP samples. Within the surgical degenerate
cohort sema3A was detected in only one sample with no
sema3F expression detected in any degenerate AF sam-
ples. Sema3A expression was observed in three degener-
ate NP samples.
Expression of receptor genes in IVD samples
NRP-1 was expressed in the healthy AF cells, but not by
the NP. In degenerate samples expression was seen in six
NP samples with no expression in AF samples (Figure 1).
N R P - 2  e x p r e s s i o n  w a s  o b s e r v e d  i n  b o t h  h e a l t h y  a n d
degenerate NP samples with four healthy NP, degenerate
AF and degenerate NP samples demonstrating positivity,
albeit at differing levels. PLXA1 expression was not
detected in any sample. PLXA2 was not detected in the
healthy disc, but expressed in the degenerate disc. PLXA3
was expressed widely across all regions in both the
healthy and degenerate disc and was found to be positive
in 80% of samples. PLXA4 was expressed in two degener-
ate AF and NP samples with little expression in healthy
IVD tissues. No PGP9.5 expression was observed in any
of the samples.
Immunohistochemistry
Immunohistochemical localisation of sema3A
Immunoreactivity to the sema3A antibody was clearly
identifiable throughout the entire cohort of IVD samples.
Staining was primarily intracellular although some peri-
cellular staining was also observed. Both the fibroblast-Tolofari et al. Arthritis Research & Therapy 2010, 12:R1
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like cells of the AF and the chondrocyte-like cells of the
NP stained positively (Figure 2). Immunoreactivity was
also observed in vascular endothelial cells. In addition,
the smooth muscle cells in the tunica media of small
blood vessels, located primarily in the OAF of the more
degenerate disc samples (grades 9 to 12) also exhibited
positive staining. Of note, smooth muscle and endothelial
cells were not counted for statistical analysis with only
the chondrocyte-like cells of the NP and AF considered as
sema3A immunopositive positive cells. There was no sig-
nificant staining within the extracellular matrix of any of
the disc samples.
Immunohistochemical localisation in the healthy disc
Immunopositivity was localised primarily to cells within
the AF with approximately 80% of cells demonstrating
positivity for sema3A (Figure 3). A gradient of expression
was observed more proximally in the disc as the cells of
the IAF showed 40% positivity and the NP cells only
showed 5% positivity. There were significant differences
(P ≤ 0.01) in the number of cells demonstrating positivity
for sema3A between all three morphological regions of
the IVD (Figure 3).
Immunohistochemical localisation in the degenerate disc
Expression of sem3A in the OAF decreased significantly
in the mildly degenerate cohort (grades 4 to 6) compared
to that of healthy OAF (P ≤ 0.01) (Figure 3). Percentage
cell immunopositivity for sema3A was 33% in the mildly
degenerate OAF compared to 26% in the IAF and 19% in
the NP, although these differences were not significant (P
≥ 0.05).
In moderately degenerate disc samples, immunoreac-
tivity decreased to 12% in the OAF, 21% in the IAF and
incr eased t o  18% in  t h e NP w hen  c om pa r ed t o m il dl y
degenerate samples. This positivity was found almost
exclusively in cell clusters of the NP. No significant differ-
ences were found between the regions of the IVD. How-
ever, there were significant differences (P  ≤ 0.05 and
0.005) between the IAF and OAF of the moderately
degenerate and healthy disc respectively (Figure 3). The
severely degenerate disc samples showed a reduction in
the number of sema3A immunopositive cells compared
to the healthy disc with the OAF and IAF having 2.2% and
5.8% immunopositive cells respectively, which were sig-
nificantly lower than expression in the healthy disc (P ≥
0.001 and P ≥ 0.005). The number of sema3A immunopo-
Conventional RT-PCR for the house-keeping gene GAPDH, semaphorin 3A, 3F and their receptors
Figure 1 Conventional RT-PCR for the house-keeping gene GAPDH, semaphorin 3A, 3F and their receptors. This is a representative photo-
graph following agarose gel electrophoresis of products from reverse transcription polymerase chain reaction for GAPDH, sema3A, sema3F, NRP-1, 
NRP-2, PLXA1, PLXA2, PLXA3, PLXA4 and PGP9.5. cDNA samples consisted of 14 healthy (non-degenerate) and 14 surgical (degenerate)intervertebral 
disc samples, with seven annulus fibrosus and seven nucleus pulposus in each. A 100 bp Hyperladder IV molecular weight marker (Mw) was included 
to allow estimation of correct band molecular weights. * represents samples assumed to be NP due to the nature of surgical intervention and sample 
collection technique.Tolofari et al. Arthritis Research & Therapy 2010, 12:R1
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sitive cells in the NP was significantly increased (P ≥ 0.05)
when compared to cells in the healthy disc with approxi-
mately 30% of cells (chondrocyte-like cell clusters) stain-
ing positively (Figure 2). Significant differences were also
seen between regions of the disc (P ≥ 0.05).
The degenerate sample cohort was further analysed to
assess any differences in numbers of immunopositive
cells between post mortem degenerate and surgical
(symptomatic patients) degenerate samples (Figure 4).
The average total disc sema3A cell immunopositivity in
the PM degenerate cohort was 32%, while in the surgical
degenerate cohort it was 12%. This reduction in sema3A
expression was significant (P ≤ 0.05). When comparing
the surgical degenerate cohort to the healthy samples,
which showed an average 50% cell immunopositivity, a
markedly significant difference was observed (P ≤ 0.001)
(data not shown).
Immunohistochemical localisation of PGP9.5
The staining within the disc was sparse and specific to
neuronal cells (Figure 5) with no positivity within the
extracellular matrix of the disc. Immunopositivity was
mainly localised to the areas of the OAF and IAF. Staining
was intracellular, but had a granular appearance. Of the
healthy cohort, 20% (2/10) of IVD samples demonstrated
positivity while 8% (1/12) of PM degenerate samples
showed areas of immunopositivity. Of the surgical degen-
erate samples 39% (7/18) showed positivity for PGP9.5.
Immunohistochemical localisation of sema3A in the healthy and degenerate disc
Figure 2 Immunohistochemical localisation of sema3A in the healthy and degenerate disc. (a) Healthy outer annulus fibrosus with cells dem-
onstrating immunopositivity for sema3A with approximately 80% of the elongated AF cells being positive. Arrows highlight negative AF cells. (b) De-
generate NP demonstrating immunopositivity in the majority of chondrocyte-like cell clusters. (c) OAF in severely degenerate disc demonstrating a 
low immunopositivity. Arrows highlight positive AF cells. (d) Healthy OAF with the sema3A antibody omitted used as a negative control.Tolofari et al. Arthritis Research & Therapy 2010, 12:R1
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Immunohistochemical localisation of CD31
Endothelial cells found within the disc were immunopos-
itive for CD31 with staining found exclusively in endothe-
lial cells surrounding developing blood vessels (Figure 5).
The chondrocyte-like cells of the AF and NP were nega-
tive. No staining was observed within the extracellular
matrix of the respective regions of the disc. Of the healthy
samples only 20% (2/10) demonstrated positivity for
CD31, 0% of the PM degenerate samples were positive,
while 56% (10/19) of the surgical samples showed some
level of positivity. Of note, five of the 10 CD31 positive
samples were also positive for PGP9.5. Interestingly, the
surgical degenerate cohort showed the lowest level of
sema3A immunopositivity.
Discussion
Evidence suggests that up to a third of adults in the UK
suffer from chronic back pain at any one time [51]. The
mechanism behind development of discogenic pain is not
fully understood. However, nociceptive nerve fibres have
been described within degenerate IVDs and there is
developing evidence supporting their role in discogenic
low back pain [14,16,18]. Although several studies have
reported the involvement of stimulatory factors in regu-
lating neural ingrowth in the IVD [17-19,21,22], the role
of potential axonal inhibitory factors, other than aggre-
can [27,28], has not been studied.
Our study is the first to localise expression of sema3A
(an axonal inhibitory molecule) in the IVD and as such
we have established a distinct regional variation in
Histogram illustrating the percentage of cells positive for sema3A per morphological region and stage of degeneration
Figure 3 Histogram illustrating the percentage of cells positive for sema3A per morphological region and stage of degeneration. Values are 
mean ± SEM. *P < 0.05.
Histogram illustrating the percentage of cells positive for 
sema3A in post-mortem degenerate samples and surgical 
degenerate 'painful' samples
Figure 4 Histogram illustrating the percentage of cells positive 
for sema3A in post-mortem degenerate samples and surgical de-
generate 'painful' samples. Values are mean ± SEM. *P < 0.05.Tolofari et al. Arthritis Research & Therapy 2010, 12:R1
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expression throughout the disc. We also observed
changes in expression patterns during degeneration. Our
immunohistochemical data demonstrated a high expres-
sion of sema3A in the cells of the OAF (approximately
80%) in the healthy disc which steadily declined towards
the NP (5%). From current literature it appears that
sema3A may act primarily as a chemorepellent factor
against neurons and blood vessels and recent evidence
suggests that sema3A is expressed by prehypertrophic
and hypertrophic chondrocytes during endochondral
ossification which precedes neurovascular invasion [47].
Our gene and protein expression results would therefore
suggest that sema3A acts as a repellent to neurons in the
healthy IVD and is expressed highly in the OAF as a
potential obstruction to neural ingrowth.
Immunohistochemistry (IHC) data demonstrated that
with degeneration there was a reduction in the total num-
ber of sema3A immunopositive cells with the severely
and surgical degenerate samples having the lowest num-
ber of immunopositive cells. Areas of the degenerate
OAF were particularly deprived of sema3A expression in
comparison to the healthy disc, demonstrating a signifi-
cant difference between PM normal and surgical degen-
erate or painful  samples. Of note, our IHC findings
demonstrated an increased PGP9.5 and CD31 expression
in the IAF and OAF of the surgical degenerate samples in
comparison to the healthy, indicating that more neuronal
and endothelial cell types were present in these samples.
Again, this supports our hypothesis that as expression of
sema3A is reduced with degeneration, there is a disinhi-
bition of neural and vascular ingrowth.
CD31, an endothelial marker, was expressed most
highly in surgical degenerate disc samples localised pri-
marily to the OAF and IAF. This suggests that the surgical
s a m p l e s  w e r e  i n f i l t r a t e d  w i t h  b l o o d  v e s s e l s  t o  a  h i g h
degree. Sema3A and isoforms of VEGF share the same
co-receptor, the neuropilins [45,46]. Sema3A and VEGF
compete for overlapping binding sites on the NRPs and
therefore competitively inhibit one another [52]. We have
shown that as the disc degenerates sema3A expression is
reduced. This reduction in sema3A essentially withdraws
the competition against VEGF and may therefore allow
angiogenesis to occur as a result of VEGF binding. Con-
versely, VEGF has also been described as a survival factor
for cells of the NP as it is expressed highly in hypoxic con-
ditions [53]. As the disc degenerates and the cartilaginous
endplates become calcified the disc tissue supposedly
becomes hypoxic. These hypoxic conditions may be a
driving force for VEGF upregulation which may cause
inhibition of sema3A activity through competitive recep-
tor binding.
In the healthy disc, very little sema3A was expressed in
the NP, however with degeneration this trend changed
and the NP became the predominant region of sema3A
gene and protein expression in more degenerate samples.
The IHC data demonstrated that this NP expression was
localised almost exclusively to cell clusters. Clustering of
these chondrocyte-like cells in the nucleus is a known
characteristic of degenerate disc tissue and is thought to
be due to increased cellular proliferation [54]. Sema3A
has been investigated concerning its role in the modula-
tion of cell proliferation [55]. Therefore there may be a
potential role for sema3A in modulating the proliferation
Immunohistochemical localisation of CD31 and PGP9.5 staining in the disc
Figure 5 Immunohistochemical localisation of CD31 and PGP9.5 staining in the disc. (a) OAF of degenerate disc with neurovascular ingrowth 
staining positive for PGP9.5. (b) OAF illustrating blood vessel ingrowth in the degenerate disc, demonstrating positive endothelial cell staining for 
CD31.Tolofari et al. Arthritis Research & Therapy 2010, 12:R1
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of cells in these clusters. Alternatively this increase in
expression during degeneration may be part of a repair or
rescue mechanism to prevent neural ingrowth into the
delicate NP region of the disc.
Data provided from the RT-PCR results have shown
that the disc cells express a number of candidate recep-
tors for the Class 3 semaphorins. For example, sema3A
has a high affinity for NRP-1 and NRP-1 was expressed
highly by the disc cells as well as PLXA3. This suggests
that sem3A may be secreted by a healthy disc cell and
then bind to a NRP-1 molecule on the same cell or a
neighbouring cell. The in vivo biological roles of the
semaphorins are not fully understood, however sema3A
plays a role in cell adhesion and migration [32,39], so
there is potential that sema3A and to a lesser extent 3F
may play a role in cell migration and distribution in the
matrix. In support of this postulation, PLXA3 transfected
MDCK cells have been shown to repel surrounding mes-
enchymal cells [56,57]. A similar phenomenon may occur
in the IVD , which ma y be a reason tha t IVD cells are
found so sparsely in the NP.
Conclusions
From the evidence provided by this study we can con-
c l u d e  t h a t  s e m a 3 A  i s  i n d e e d  e x p r e s s e d  b y  c e l l s  o f  t h e
healthy IVD, primarily OAF cells. This expression
decreases with IVD degeneration and of note disc sam-
ples that have already exhibited neural ingrowth show the
lowest expression of sema3A in comparison to healthy
samples. The regulation of neurovascular growth into the
degenerate intervertebral disc is quite clearly multifacto-
rial as evidenced by a number of studies investigating dif-
ferent potential mechanisms for this phenomenon. Of
note, it may not just be neurotrophic or chemorepellent
factors that play a role in nerve growth regulation, but it
may also be the complex alterations in the biochemical
constituents of the extracellular matrix occurring during
disc degeneration that influence neurovascular develop-
ment/ingrowth in the disc. Previously mentioned studies
[25,26] have discussed potential causative mechanisms
for neural ingrowth regarding matrix degradation and
have emphasised the role of molecules such as aggrecan
in the regulation of neuronal growth. However, from evi-
dence provided by our study, we can postulate that
sema3A is expressed in high levels in the OAF of the disc
as an additional or alternative means of preventing neural
ingrowth, and as degeneration progresses we see a loss of
inhibition and therefore the growth of invading nocicep-
tive neurons into the otherwise aneural IVD. We propose
that this may be a potential mechanism for the pathogen-
esis of chronic low back pain.
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